Exagamglogene autotemcel, sold under the brand name Casgevy, is a gene therapy used for the treatment of sickle cell disease and transfusion-dependent...
20 KB (1,433 words) - 11:58, 8 August 2024
cell anemia by inhibiting the BCL11A gene have been developed. Exagamglogene autotemcel, sold under the brand name Casgevy, is a gene therapy for the treatment...
59 KB (5,416 words) - 03:19, 9 August 2024
developing red blood cells, with resultant resolution of the anemia. Exagamglogene autotemcel, sold under the brand name Casgevy, is a gene therapy for the treatment...
67 KB (7,150 words) - 22:54, 2 August 2024
the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel (formerly CTX001), was granted regulatory approval...
11 KB (918 words) - 14:13, 19 April 2024
Crizanlizumab B06AX02 Betibeglogene autotemcel B06AX03 Voxelotor B06AX04 Mitapivat B06AX05 Exagamglogene autotemcel "ATC (Anatomical Therapeutic Chemical...
960 bytes (213 words) - 02:49, 18 December 2023
like deferoxamine, deferiprone and luspatercept. Gene therapy, exagamglogene autotemcel is approved for medical use in the United Kingdom since November...
32 KB (3,700 words) - 04:56, 23 July 2024
Evenity everolimus (USAN) Evex Evista Evolocumab (INN) Evoxac exagamglogene autotemcel (INN) exalamide (INN) exametazime (INN) examorelin (INN) exaprolol...
2 KB (198 words) - 03:04, 1 July 2024
Exo-cell may be a misspelling of: Exa-cell, exagamglogene autotemcel Exocell, an organism in the video game Cold Fear This disambiguation page lists articles...
159 bytes (52 words) - 10:21, 1 April 2024
developing red blood cells, with resultant resolution of the anemia. Exagamglogene autotemcel, sold under the brand name Casgevy, is a gene therapy for the treatment...
44 KB (4,881 words) - 01:25, 1 August 2024
dezaparvovec (Hemgenix): AAV-based treatment for hemophilia B Exagamglogene autotemcel (Casgevy): treatment for sickle cell disease. Gendicine: treatment...
10 KB (792 words) - 10:27, 12 December 2023
Therapeutics that led to the discovery and development of Casgevy, (exagamglogene autotemcel; formerly known as CTX001), the first gene editing treatment to...
28 KB (2,399 words) - 20:10, 25 July 2024
the most expensive drug ever. In May, the EMA approved betibeglogene autotemcel (Zynteglo) for treating beta thalassemia for people twelve years of age...
174 KB (17,957 words) - 10:42, 6 August 2024
to determine their effectiveness. In 2023, both exagamglogene autotemcel and lovotibeglogene autotemcel were approved for the treatment of sickle cell...
141 KB (15,222 words) - 11:55, 12 August 2024
to treat sickle-cell anemia and beta thalassemia. Casgevy, or exagamglogene autotemcel, directly acts on the genes of the stem cells inside the patient's...
170 KB (19,936 words) - 16:29, 8 August 2024